PMID- 38219142
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240226
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 26
IP  - 3
DP  - 2024 Mar
TI  - Predictive factors that influence the clinical efficacy of umbilical cord-derived 
      mesenchymal stromal cells in the treatment of type 2 diabetes mellitus.
PG  - 311-316
LID - S1465-3249(24)00002-1 [pii]
LID - 10.1016/j.jcyt.2023.12.006 [doi]
AB  - BACKGROUND: Our previous single-center, randomized, double-blinded, 
      placebo-controlled phase 2 study evaluated the safety and effectiveness of human 
      umbilical cord mesenchymal stromal cell (UC-MSC) transfusion for treating 
      patients with type 2 diabetes mellitus (T2DM). Indeed, this potential treatment 
      strategy was able to reduce insulin use by half in a considerable number of 
      patients. However, many other patients' responses to UC-MSC transfusion were 
      insignificant. The selection of patients who might benefit from UC-MSC treatment 
      is crucial from a clinical standpoint. METHODS: In this post hoc analysis, 37 
      patients who received UC-MSC transfusions were divided into two groups based on 
      whether their glycated hemoglobin (hemoglobin A1c, or HbA1c) level was less than 
      7% after receiving UC-MSC treatment. The baseline differences between the two 
      groups were summarized, and potential factors influencing efficacy of UC-MSCs for 
      T2DM were analyzed by univariate and multivariate logistic regression. The 
      correlations between the relevant hormone levels and the treatment effect were 
      further analyzed. RESULTS: At the 9-week follow-up, 59.5% of patients achieved 
      their targeted HbA1c level. Male patients with lower baseline HbA1c and greater 
      C-peptide area under the curve (AUCC-pep) values responded favorably to UC-MSC 
      transfusion, according to multivariate analysis. The effectiveness of UC-MSCs 
      transfusion was predicted by AUCC-pep (cutoff value: 14.22 ng/h/mL). Further 
      investigation revealed that AUCC-pep was increased in male patients with greater 
      baseline testosterone levels. CONCLUSIONS: Male patients with T2DM with greater 
      AUCC-pep may be more likely to respond clinically to UC-MSC therapy, and further 
      large-scale multi-ethnic clinical studies should be performed to confirm the 
      conclusion.
CI  - Copyright (c) 2024 International Society for Cell & Gene Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Wang, Yuepeng
AU  - Wang Y
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China; School of Medicine, Nankai University, Tianjin, China.
FAU - Chen, Haixu
AU  - Chen H
AD  - Institute of Geriatrics & National Clinical Research Center of Geriatrics 
      Disease, The Second Medical Center of Chinese PLA General Hospital, Beijing, 
      China.
FAU - Li, Yijun
AU  - Li Y
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Hao, Haojie
AU  - Hao H
AD  - Department of Biotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Liu, Jiejie
AU  - Liu J
AD  - Department of Biotherapy, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Chen, Yulong
AU  - Chen Y
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Meng, Junhua
AU  - Meng J
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Zhang, Saichun
AU  - Zhang S
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Gu, Weijun
AU  - Gu W
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Lyu, Zhaohui
AU  - Lyu Z
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China.
FAU - Zang, Li
AU  - Zang L
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China. Electronic address: zangli301@163.com.
FAU - Mu, Yiming
AU  - Mu Y
AD  - Department of Endocrinology, The First Medical Center of Chinese PLA General 
      Hospital, Beijing, China. Electronic address: muyiming@301hospital.com.cn.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20240113
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Glycated Hemoglobin)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Diabetes Mellitus, Type 2/therapy/metabolism
MH  - Glycated Hemoglobin
MH  - Umbilical Cord
MH  - Treatment Outcome
MH  - *Mesenchymal Stem Cells/physiology
MH  - *Mesenchymal Stem Cell Transplantation
OTO - NOTNLM
OT  - C-peptide area under the curve
OT  - glycated hemoglobin
OT  - male
OT  - mesenchymal stromal cells
OT  - testosterone
OT  - type 2 diabetes mellitus
COIS- Declaration of Competing Interest The authors have no commercial, proprietary or 
      financial interest in the products or companies described in this article.
EDAT- 2024/01/14 14:42
MHDA- 2024/02/26 06:43
CRDT- 2024/01/14 10:34
PHST- 2023/09/02 00:00 [received]
PHST- 2023/11/20 00:00 [revised]
PHST- 2023/12/26 00:00 [accepted]
PHST- 2024/02/26 06:43 [medline]
PHST- 2024/01/14 14:42 [pubmed]
PHST- 2024/01/14 10:34 [entrez]
AID - S1465-3249(24)00002-1 [pii]
AID - 10.1016/j.jcyt.2023.12.006 [doi]
PST - ppublish
SO  - Cytotherapy. 2024 Mar;26(3):311-316. doi: 10.1016/j.jcyt.2023.12.006. Epub 2024 
      Jan 13.